Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Schering Pharma voices commitment to cancer treatments

Bayer Schering Pharma voices commitment to cancer treatments

1st June 2009

Bayer Schering Pharma is committed to discovering new cancer-fighting therapies, it has asserted.

The company released data from clinical trials of a potent oral multi-kinase inhibitor Bay 73-4506, which is being examined in a number of tumour types.

Results showed a 79 per cent disease control rate and a 27 per cent partial response level.

Head of global development at the firm Dr Kemal Malik said he is encouraged by the investigations so far.

“This data will help further determine our next steps as we move forward with a comprehensive ? clinical development program in various tumour types for this new drug candidate,” he commented.

Last week, Bayer Healthcare announced it was due to start phase III studies of Nexavar (sorafenib) tablets in conjunction with Tarceva (erlotinib) tablets to see how effective they were at managing patients with advanced hepatocellular carcinoma.

The medication is the only approved targeted therapy for tolerability and efficacy in liver cancer and Dr Dimitris Voliotis, vice-president of the drug’s clinical development, said he looks forward to seeing the full potentials of the medication when combined with other therapies.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.